Immunotherapies for COVID-19: lessons learned from sepsisKenneth E. Remy, Lyle L. Moldawer, Scott C. Brakenridge et al.|The Lancet Respiratory Medicine|2020Cited by 165
Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trialThomas Daix, Bruno François, Michel Morre et al.|Annals of Intensive Care|2023Cited by 76
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal studyMonica Kraft, Nadine Rouphael, Holden T. Maecker et al.|Science Immunology|2021Cited by 74
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC studyAl Ozonoff, Joanna Schaenman, Naresh Doni Jayavelu et al.|EBioMedicine|2022Cited by 73
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC studyAl Ozonoff, Brenda Barton, Naresh Doni Jayavelu et al.|Nature Communications|2024Cited by 58